Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Gilteritinib, a highly potent FLT3 inhibitor, has demonstrated promising clinical outcomes in adults with relapsed/refractory (R/R) FLT3-mutated AML [111]
The IV drip therapy involves no downtime, so you can resume your day as soon as you are done
Patients should contact their GP or diabetes specialist nurse if they experience unexpected changes in blood glucose control, significant gastrointestinal symptoms, or concerns about dietary modifications whilst on GLP-1 therapy
2014 Oct 17;7:267-74
US$ 23.98
US$ 21.10
US$ 28.16
US$ 28.34
US$ 28.34
